Prevagen Study Data Withstand False Ad Complaint By FTC, New York AG
This article was originally published in The Rose Sheet
Executive Summary
A federal judge dismissed a complaint filed by FTC and New York AG Schneiderman against Quincy Biosciences about claims for Prevagen cognitive supplement. The complaint did not show the company violated the FTC Act because it pointed only to possible errors in a supporting study.
You may also be interested in...
FTC’s Monetary Relief Claims Dismissed In Prevagen Fraud Case; Supreme Court Decision Cited
The Federal Trade Commission’s claim for monetary relief against the Prevagen memory supplement marketer is dismissed by a federal judge in New York, who cites recent Supreme Court decision gutting the agency's long-favored mechanism for collecting monetary penalties under the FTC Act.
Prevagen ‘Improves Memory’ Claims Will Be Qualified Under Class Action Settlement
Quincy Bioscience doesn’t admit to “any liability or wrongdoing of any kind associated with the claims alleged” in settlement to complaint in federal court in Florida, but agrees to pay plaintiffs refunds of 30% of the MSRP for its supplements, up to $70 per individual claimant.
Fewer Arrows Left In Quincy's Quiver To Defend Against FTC's Prevagen Supplement Complaint
"There is no need to litigate the same issue again," says District Judge Louis Stanton in granting most of the joint motions by FTC and New York attorney general to strike Quincy Bioscience's proposed defenses. The judge denied other motions, including whether NY state laws are applicable, saying a trial is needed to weigh the evidence.